Abstract
Retinal vein occlusion (RVO) is most commonly seen in middle-aged or older patients and is associated with underlying cardiovascular risk factors. It is much less common in younger patients. Use of the oral contraceptive pill (OCP) is known to be a risk factor for cardiovascular and cerebrovascular disease. There have previously been a few isolated case reports of patients sustaining an RVO whilst taking the OCP. The aim of this study was to investigate patients sustaining an RVO whilst taking the OCP or hormone replacement therapy (HRT). From a large series of 588 patients, we found 11 with an RVO associated with sex hormone preparations. Of these, 6 had taken the OCP and 5 were HRT users. From this large group there were only 9 female patients aged under 35 years who sustained an RVO. Of these, 6 were associated with use of the OCP. All patients were investigated for recognised medical risk factors for RVO. None of these factors were identified in the patients who had used the OCP. Of the patients taking HRT, 4 of the 5 had other potential risk factors. From our large series, the prevalence of RVO in female patients under 35 years taking the OCP was 66%. There is a 30% uptake of the OCP in the general population. These data support the view that RVO is a contraindication to the use of the OCP. Additionally, it would appear (albeit from limited data) that patients who sustain RVO may continue with their HRT, as HRT is not a major single risk factor for RVO.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Sorsby A . The incidence and causes of blindness in England and Wales. London: HMSO, 1978:1963–8.
Klein BA . Occlusion of the central retinal vein: clinical importance of certain histo-pathologic observations. Am J Ophthalmol 1953;36:316–24.
Rabinowicz IM, Litman S, Michaelson IC . Branch venous thrombosis: a pathological report. Trans Ophthalmol Soc UK 1968;88:191–210.
Dodson PM, Kritzinger EE . Underlying medical conditions in young patients and ethnic differences in retinal vein occlusion. Trans Ophthalmol Soc UK 1985;104:114–9.
Vessey MP . Female hormones and vascular disease: an epidemiological overview. Br J Farn Plann 1980;6:1–12.
Helmrich SP, Rosenberg L, Kaufman DW, Strom B, Shapiro S . Venous thromboembolism in relation to oral contraceptive use. Obstet Gynecol 1987;69:91–5.
Vessey MP, Lawless M, Yeates D . Oral contraceptives and stroke: findings in a large prospective study. BMJ 1984;289:530–1.
La Veccia C . Sex hormones and cardiovascular risk. Hum Reprod 1992;7:162–7.
Grimes DA . The safety of oral contraceptives: epidemiologic insights from the first 30 years. Am J Obstet Gynecol 1992;166:1950–4.
Thorogood M, Villard-Macintosh L . Combined oral contraceptives: risks and benefits. Br Med Bull 1993;49:124–39.
Foster K, Jackson B, Thomas M, Hunter P, Bennett N . Contraception. In: General household survey. London: HMSO, 1993:113–36.
Godsland IF, Crook D, Wynn V . Clinical and metabolic considerations of long term oral contraceptive use. Am J Obstet Gynecol 1992;166:1955–63.
Fong ACO, Schatz H . Central retinal vein occlusion in young adults. Surv Ophthalmol 1993;37:393–417.
Cecily C, Kelleher MD . Clinical aspects of the relationship between oral contraceptives and abnormalities of the coagulation system: relation to the development of cardiovascular disease. Am J Obstet Gynecol 1990;163:392–5.
Bonnar J . Coagulation effects of oral contraception. Am J Obstet Gynecol 1987;157:1042–8.
Prentice RL . On the ability of blood pressure effects to explain the relation between oral contraceptives and cardiovascular disease. Am J Epidemiol 1988;127:213–9.
Wynn V, Adams PW, Godsland I, et al. Comparison of effects of different combined oral-contraceptives on carbohydrate and lipid metabolism. Lancet 1979;1:1049–54.
Fotherby K . Update on lipid metabolism and oral contraception. Br J Farn Plann 1990;15:23–6.
Lobo RA, Speroff L . International consensus conference on postmenopausal hormone therapy and the cardiovascular system. Fertil Steril 1994;61:592–5.
Meade TW, Berra A . Hormone replacement therapy and cardiovascular disease. Br Med Bull 1992;48:276–308.
Lobo RA . The role of progestins in hormone replacement therapy. Am J Obstet Gynecol 1992;166:1997–2003.
Meade TW, Stanwell-Smith R . Hormone replacement therapy for menopausal women: a review of its effects on homeostatic function, lipids, and blood pressure. Adv Drug Reac Rev 1984;4:187–210.
Lip GY, Beevers M, Churchill D, Beevers DG . Hormone replacement therapy and blood pressure in hypertensive women. J Hum Hypertens 1994;8:491–4.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kirwan, J., Tsaloumas, M., Vinall, H. et al. Sex hormone preparations and retinal vein occlusion. Eye 11, 53–56 (1997). https://doi.org/10.1038/eye.1997.11
Issue date:
DOI: https://doi.org/10.1038/eye.1997.11
Keywords
This article is cited by
-
Practical Management of Retinal Vein Occlusions
Ophthalmology and Therapy (2012)
-
The platelet glycoprotein Ia/IIa gene polymorphism C807T/G873A: a novel risk factor for retinal vein occlusion
Eye (2003)
-
Central retinal vein occlusion and thrombophilia
Eye (2002)
-
A transsexual patient with bilateral central retinal vein occlusions
Eye (2000)
-
Drug or drusen? Central retinal vein occlusion in a young healthy woman with disc drusen
Eye (2000)
